CN101511388B - 含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途 - Google Patents

含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途 Download PDF

Info

Publication number
CN101511388B
CN101511388B CN2007800332946A CN200780033294A CN101511388B CN 101511388 B CN101511388 B CN 101511388B CN 2007800332946 A CN2007800332946 A CN 2007800332946A CN 200780033294 A CN200780033294 A CN 200780033294A CN 101511388 B CN101511388 B CN 101511388B
Authority
CN
China
Prior art keywords
gaba
pain
chemical moiety
nortriptyline
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800332946A
Other languages
English (en)
Chinese (zh)
Other versions
CN101511388A (zh
Inventor
A·努德尔曼
A·雷法利
I·吉尔-阿德
A·韦兹曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Bar Ilan University
Original Assignee
Ramot at Tel Aviv University Ltd
Bar Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Bar Ilan University filed Critical Ramot at Tel Aviv University Ltd
Publication of CN101511388A publication Critical patent/CN101511388A/zh
Application granted granted Critical
Publication of CN101511388B publication Critical patent/CN101511388B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800332946A 2006-07-17 2007-07-17 含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途 Expired - Fee Related CN101511388B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83119206P 2006-07-17 2006-07-17
US83119506P 2006-07-17 2006-07-17
US60/831,192 2006-07-17
US60/831,195 2006-07-17
PCT/IL2007/000903 WO2008010223A2 (en) 2006-07-17 2007-07-17 Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders

Publications (2)

Publication Number Publication Date
CN101511388A CN101511388A (zh) 2009-08-19
CN101511388B true CN101511388B (zh) 2012-10-24

Family

ID=38621178

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800332946A Expired - Fee Related CN101511388B (zh) 2006-07-17 2007-07-17 含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途

Country Status (11)

Country Link
US (3) US8222296B2 (enExample)
EP (1) EP2051735B1 (enExample)
JP (1) JP5192485B2 (enExample)
KR (1) KR20090048462A (enExample)
CN (1) CN101511388B (enExample)
AU (1) AU2007274583B2 (enExample)
CA (1) CA2659521A1 (enExample)
ES (1) ES2393933T3 (enExample)
IL (1) IL196538A0 (enExample)
MX (1) MX2009000641A (enExample)
WO (2) WO2008010223A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
CA2610838A1 (en) * 2005-06-07 2006-12-14 Ramot At Tel Aviv University Ltd. Novel salts of conjugated psychotropic drugs and processes of preparing same
WO2008010223A2 (en) 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
US20090074677A1 (en) * 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
EP2252578B1 (en) * 2008-02-11 2012-08-01 Ramot at Tel Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
WO2010027266A1 (en) * 2008-09-05 2010-03-11 Van De Langenberg, Hendrikus Theodorus Ardina Hubertus Means and methods for counteracting neurological disorders
KR101810246B1 (ko) 2008-10-08 2017-12-18 엑스진 파마슈티컬 인크. Ｇａｂａ 접합체 및 그의 사용 방법
WO2010110916A2 (en) * 2009-03-26 2010-09-30 Seventh Sense Biosystems, Inc. Determination of tracers within subjects
US8141697B2 (en) * 2009-04-03 2012-03-27 Ackley Machine Corporation Method and apparatus for transporting caplets
CA2774008C (en) * 2009-09-23 2017-06-20 The Regents Of The University Of Colorado, A Body Corporate Toll-like receptor modulators and uses thereof
AU2010329440A1 (en) * 2009-12-09 2012-08-09 Bar-Ilan University Methods of improving cognitive functions
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
JP5893135B2 (ja) * 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
WO2014022807A2 (en) * 2012-08-03 2014-02-06 Alumend, Llc Compositions and methods of using the compositions for plaque softening
CA3207643A1 (en) * 2015-09-23 2017-03-30 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
BR112019020464A2 (pt) 2017-03-30 2020-04-28 Xw Laboratories Inc. compostos derivados de heteroarila bicíclica, composição farmacêutica compreendendo os ditos compostos, adesivo transdérmico compreendendo a dita composição e uso terapêutico dos compostos e composição
WO2018199174A1 (ja) * 2017-04-25 2018-11-01 生化学工業株式会社 第３級アミン化合物又はイミン化合物－ポリマーコンジュゲートとその製造方法
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP4227293A3 (en) * 2018-05-14 2023-10-04 Xgene Pharmaceutical Inc Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin
ES2947089T3 (es) 2018-09-30 2023-08-01 Xwpharma Ltd Compuestos como antagonistas del receptor histamínico 3 neuronal y usos de los mismos
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
WO2021127461A1 (en) 2019-12-20 2021-06-24 Xw Laboratories Limited Methods of synthesizing 4-valyloxybutyric acid
KR20230008190A (ko) 2020-06-18 2023-01-13 엑스더블유파마 리미티드 수용성 원료의약품의 약학적 과립화제
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
EP4308086B1 (en) 2021-03-19 2025-10-15 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
CN114452256A (zh) * 2021-12-31 2022-05-10 浙江大学 脊髓损伤靶向药物、聚合物-疏水化合物胶束及其制备方法
CN115057865B (zh) * 2022-05-10 2023-03-31 国药集团工业有限公司 一种磷酸可待因半水合物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026563A2 (en) * 2001-09-27 2003-04-03 Ramot At Tel Aviv University Ltd. Conjugated anti-psychotic drugs and uses thereof
WO2005092392A2 (en) * 2004-03-25 2005-10-06 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20060058219A1 (en) * 2004-09-14 2006-03-16 Miller Landon C Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2944053A (en) * 1960-07-05 Uiiilcu
US3058979A (en) 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
US2914528A (en) 1958-04-16 1959-11-24 Smith Kline French Lab Substituted phenothiazinyl trifluoro-methyl sulfones
NL105973C (enExample) 1957-09-11 1900-01-01
US2969358A (en) 1958-12-08 1961-01-24 Searle & Co 2-chloro-10-phenothiazinecarbonylpiperazines
GB1460713A (en) 1973-06-08 1977-01-06 Kefalas As 7-fluoro substituted phenothiazines method for preparation thereof and compositions bladed rotor for a gas turbine engine
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US3978216A (en) * 1974-06-03 1976-08-31 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US3956493A (en) 1974-10-21 1976-05-11 E. R. Squibb & Sons, Inc. Long acting tranquilizing agent
GB1540842A (en) * 1976-08-25 1979-02-14 Kefalas As Phenothiazines
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
JPS6072868A (ja) 1982-10-04 1985-04-24 Fujisawa Pharmaceut Co Ltd 縮合複素環誘導体およびその製造法
US4629691A (en) * 1983-08-01 1986-12-16 Syntex (U.S.A.) Inc. Tricyclic antidepressant conjugates with antigens and enzymes
GB8413605D0 (en) 1984-05-29 1984-07-04 Gersan Ets Examining unfinished gemstone
US5051448A (en) * 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
JPS62501991A (ja) 1985-02-15 1987-08-06 ザ　ブロ−クン　ヒル　プロプライエタリイ　カンパニ−　リミテツド 鋼鉄の分類
WO1986004991A1 (en) 1985-02-15 1986-08-28 The Broken Hill Proprietary Company Limited Classification of steel
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
ES8707175A1 (es) 1986-06-13 1987-07-16 Inke Sa Procedimiento para la obtencion de la n-metil-3-(p-trifluorometilfenoxi)-3-fenilpropilamina
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
JPH02128564A (ja) 1988-11-08 1990-05-16 Nec Corp 電話付きパーソナルコンピュータ
JP2801648B2 (ja) 1989-06-14 1998-09-21 日本化薬株式会社 ６―フルオロ―４―クロマノン―２―カルボン酸アミド又はエステルの製造法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU3244793A (en) 1991-12-09 1993-07-19 Gem International Network, Inc. Computer imaging system for gemstones
US5780590A (en) 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
WO1995014666A1 (en) 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5534522A (en) 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
JP2001519754A (ja) 1995-07-13 2001-10-23 アノーメッド・インコーポレイテッド ２−［２−（ジメチルアミノ）エチル］−８，８−ジプロピル−２−アザスピロ［４．５］デカンジマレイン酸塩
CA2162532C (en) 1995-11-09 2001-01-30 Dana J. Vanier Gemstone registration system
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
US5966673A (en) * 1997-01-10 1999-10-12 Diamond Technologies, Inc. System and method for computerized evaluation of gemstones
US6130221A (en) 1997-03-05 2000-10-10 Nymox Corporation Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6020954A (en) * 1997-12-18 2000-02-01 Imagestatistics, Inc. Method and associated apparatus for the standardized grading of gemstones
US5983238A (en) * 1997-12-26 1999-11-09 Diamond Id Gemstons identification tracking and recovery system
JP4002006B2 (ja) 1998-06-29 2007-10-31 日本電信電話株式会社 色校正装置、色校正方法、および色校正プログラムを記録した記録媒体
US20010024532A1 (en) * 1998-09-21 2001-09-27 Malnekoff Peter J. Automated gemstone evaluation system
US6304853B1 (en) 1998-09-21 2001-10-16 Peter J. Malnekoff Automated gemstone evaluation system
IL134664A0 (en) 1999-10-29 2001-04-30 Diamond And Jewelry 4 U Ltd System for trade in precious gemstones
US6381510B1 (en) * 1999-11-19 2002-04-30 Eruggallery.Com Methods and apparatus for facilitating electronic commerce in area rugs
MXPA02005275A (es) * 1999-12-01 2003-02-17 Ucb Sa Derivado de pirrolidinacetamida solo en combinacion para el tratamiento de trastornos del sistema nervioso central.
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US8706645B2 (en) 2000-05-23 2014-04-22 David W. Hendry, Jr. System and method for appraising valuable items
US20020021439A1 (en) * 2000-08-07 2002-02-21 Derek Priestley Colour matching system
US7251619B2 (en) * 2000-09-01 2007-07-31 Garry Ian Holloway Computer implemented method, computer program product, and system for gem evaluation
JP2005097120A (ja) 2000-10-06 2005-04-14 Mochida Pharmaceut Co Ltd ４−ヒドロキシピペリジン誘導体の非潮解性塩
WO2002028881A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20030065586A1 (en) * 2001-07-31 2003-04-03 Shaftel Keith L. Electronic commerce product pricing and selection system and method
US20030115079A1 (en) 2001-08-30 2003-06-19 Rapaport Martin M. Method of and system for ranking optimal values
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US20060167032A1 (en) 2002-01-16 2006-07-27 Galer Bradley S Pharmaceutical composition and method for treating disorders of the central nervous system
WO2003062942A2 (en) 2002-01-25 2003-07-31 Menahem Sevdermish A method for digital color grading of gems and communication thereof
US8046274B2 (en) 2002-01-25 2011-10-25 Menahem Sevdermish Method for digital color grading of gems and communication thereof
US20040092504A1 (en) 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
EA008864B1 (ru) 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
AU2005281359A1 (en) * 2004-08-26 2006-03-16 Apparao Satyam Prodrugs and codrugs containing novel bio-cleavable disulfide linkers
US7151084B2 (en) * 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
TW200715156A (en) 2004-11-24 2007-04-16 Interdigital Tech Corp Intelligent information dissemination using a dynamic profile
CA2610838A1 (en) * 2005-06-07 2006-12-14 Ramot At Tel Aviv University Ltd. Novel salts of conjugated psychotropic drugs and processes of preparing same
WO2007050318A2 (en) 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
ES2573733T3 (es) 2006-05-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento farmacológico del deterioro cognitivo
WO2008010223A2 (en) * 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
EP2252578B1 (en) 2008-02-11 2012-08-01 Ramot at Tel Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
CN102858345A (zh) 2010-02-24 2013-01-02 雷蒙特亚特特拉维夫大学有限公司 奋乃静-gaba的三甲磺酸盐的晶型及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026563A2 (en) * 2001-09-27 2003-04-03 Ramot At Tel Aviv University Ltd. Conjugated anti-psychotic drugs and uses thereof
WO2005092392A2 (en) * 2004-03-25 2005-10-06 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20060058219A1 (en) * 2004-09-14 2006-03-16 Miller Landon C Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders

Also Published As

Publication number Publication date
MX2009000641A (es) 2009-02-12
JP2009543858A (ja) 2009-12-10
WO2008010223A3 (en) 2008-03-20
US8222296B2 (en) 2012-07-17
AU2007274583A1 (en) 2008-01-24
CN101511388A (zh) 2009-08-19
ES2393933T3 (es) 2013-01-02
US20100144869A1 (en) 2010-06-10
CA2659521A1 (en) 2008-01-24
WO2008010222A3 (en) 2008-04-10
US20090304584A1 (en) 2009-12-10
WO2008010222A2 (en) 2008-01-24
KR20090048462A (ko) 2009-05-13
JP5192485B2 (ja) 2013-05-08
EP2051735A2 (en) 2009-04-29
WO2008010223A2 (en) 2008-01-24
US8377990B2 (en) 2013-02-19
IL196538A0 (en) 2009-11-18
EP2051735B1 (en) 2012-08-29
AU2007274583B2 (en) 2012-11-01
US20130059910A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
CN101511388B (zh) 含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途
JP6505822B2 (ja) メチルフェニデート−プロドラッグ、その製造法及び使用法
EP2252578B1 (en) Conjugates for treating neurodegenerative diseases and disorders
RU2012103476A (ru) Конъюгаты гидрокодона с бензойной кислотой, производными бензойной кислоты и гетероарилкарбоновой кислотой, пролекарства, способы их получения и их применение
JP2013523599A (ja) 新規なオピオイドのジカルボン酸結合アミノ酸及びペプチドプロドラッグ並びにその用途
KR20120060203A (ko) 신규한 오피오이드의 카바메이트 아미노산과 펩티드 프로드럭 및 그의 용도
JP2019515891A (ja) タンニン酸を含有する組成物及びその使用
KR20160111013A (ko) 신경질환의 치료를 위한 바클로펜, 아캄프로세이트 및 중쇄 트리-글리세리드의 조합
CN112494476A (zh) 用于治疗肥胖症的化合物的用途
US20150329608A1 (en) Opiorphin for use as a psychostimulant agent
JP6016179B2 (ja) 疼痛の治療又は予防用医薬組成物
JP2008515765A (ja) 新規なケリドニン誘導体、その生成法、および医薬品を生成するためのその使用
EP2877486B1 (en) Peptide-based compounds and uses thereof to treat beta-amyloid accumulation
RU2005111988A (ru) Лечение запала
JP6858325B2 (ja) 新規ペプチド及びその用途
HK1179523B (en) N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121024

Termination date: 20140717

EXPY Termination of patent right or utility model